EP-1240: Clinical outcomes of image guided adaptive radiotherapy (IGART) for hypofractionated treatment of bladder cancer  by Hafeez, S. et al.
3rd ESTRO Forum 2015                                                                                                                                         S671 
 
(μ±σ) of the volume identified by image analysis on the new 
image sets and by an experienced oncologist on the original 
image sets was 0.76±0.13 measured by the Dice similarity 
criterion (DSC). 17 cases had a DSC above 0.8; 17 cases had a 
DSC between 0.8 and 0.6; 2 cases had a DSC below 0.6. The 
figure shows the CT images from three bladder cancer 
patients. The Blue contour is the CTV; green is the CTV 
produced by thresholding of the original CT images; cyan is 
the CTV produced by thresholding of the image analysis 
enhanced CT image, which shows good agreement with the 
clinical contours using the BPJ-enhanced image data. 
Conclusions: The image analysis study presented for defining 
the CTV on low contrast CT images has the potential to be 
used as part of an adaptive radiotherapy system. Such a 
simple approach was not possible on the original image set. 
Although good agreement was found between the clinical and 
image analysis defined CTV this study serves only to provide 
pilot results. More extensive validation is required using CBCT 
and more observers. 
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Purpose/Objective: Treatment of prostate cancer in frail 
elderly patients is challenging. Many of such patients are not 
candidates for surgery, brachytherapy or SBRT. 
Conventionally fractionated radiotherapy is frequently a 
choice, but duration of such treatment appears as an 
apparent challenge for frail individuals. To address these 
problems we designed a hypofractionated split course 
radiation therapy (HSC-RT) that, potentially, allows 
treatment in reduced number of fractions without 
compromising effectiveness. Because prostate cancer does 
not repopulate rapidly split course RT was allowed. Planned 
interruption may reduce acute reactions and may facilitate 
comfortable outpatient management of patients. 
Materials and Methods: Elderly frail patients with 
intermediate or high risk prostate cancer were considered as 
candidates for the present study. Radiation dose of 62,5 Gy 
in 2.5 Gy per fraction was given over 9 weeks with two 
planned gaps of 14 days each, after accumulation of 25 Gy 
and 50 Gy. Median age of the patients in the analyzed pilot 
series of 20 patients was 76 years (range 67-83), most 
patients had impaired general performance (ZUBROD 1-2) . A 
series of 130 consecutive patients (comparable risk 
characteristics, good PS, median age of 67 years) treated 
with conventionally fractionated radiotherapy (dose of 70-76 
Gy, median 74 Gy) was used for comparison of biochemical 
outcome. Neoadjuvant ADT was used in both groups. PSA 
concentration and treatment tolerance was assessed at 
follow-up. 
Results: In general, HSC-RT was well tolerated, ( the highest 
RTOG score for bladder toxicity during treatment was 1 for 
45% of patients, 2 for 15%, 3 for 5%, rectal toxicity was 
minimal with highest score 1 in 15 % of patients. There were 
not late rectal toxicity and late bladder toxicity was minima 
with highest score 1). Baseline median pretreatment PSA 
concentration was the same in both groups (15 ng/ml). 
However, in spite of planned treatment gaps, the PSA 
measurements at follow-up revealed somewhat favorable 
biochemical outcome in patients treated with HSC-RT, 
compared to those treated conventionally (CF). Median PSA 
concentration (ng/ml) at follow-up was lower in HSC-RT 
compared to CF (0.03 vs. 0.08 at 12 months; 0.03 vs. 0.13 at 
24 months; 0.01 vs. 0.22 at 36 months). Median PSA nadir was 
0.013 ng/ml for HSC-RT vs. 0,03 for CF. 
Conclusions: While the results of this study are limited by a 
small size and clinical heterogeneity of the analyzed group 
the outcome presented suggest that hypofractionated split 
course radiation therapy in frail elderly patients with 
intermediate/high risk prostate cancer is feasible and does 
not compromise biochemical control. 
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Purpose/Objective: Anatomical variation in bladder position 
and size has driven on-line IGART strategies to prevent 
geographical misses. A ‘plan of the day’ IGART approach 
improves target coverage and reduces normal tissue 
irradiation. We report on the clinical outcomes of patients 
treated in a phase 2 study with hypofractionated 
radiotherapy using this technique.  
Materials and Methods: Fifty-five patients with T2-T4aN0-2 
M0 bladder cancer not suitable for cystectomy or daily 
radiotherapy treatment were recruited between February 
2009 and March 2014. A library of 3 plans were created (using 
small, medium and large PTV) from planning CT scans 
performed at 0 and 30 minutes, treating whole (empty) 
bladder to 36Gy in 6 weekly fractions. Cone beam CT (CBCT) 
imaging was performed prior to each fraction. Appropriate 
PTV was selected from the library for treatment delivery. 
Acute toxicity was assessed weekly during radiotherapy and 
at 6 and 12 weeks using CTCAE v3.0. Late toxicity was 
assessed at 6 months and 12 months using Radiation Therapy 
Oncology Group (RTOG) grading. Local control was assessed 
at 3 months preferentially with cystoscopy, or if this was not 
possible with imaging alone (CT/MRI). Local progression free 
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survival and overall survival were estimated using the Kaplan-
Meier method. 
Results: Median age was 85 years (range 68-97 years). There 
were 31 males and 24 females. Four deaths occurred during 
radiotherapy unrelated to treatment (3 from pneumonia and 
1 from urinary sepsis).  
Genito-urinary grade 2 and grade 3 acute toxicity was seen in 
20% and 10% respectively. Gastro-intestinal grade 2 and grade 
3 acute toxicity was seen in 9.5 % and <1% respectively. No 
grade 4 genito-urinary or gastro-intestinal toxicity was seen. 
16% reported other grade 2 acute toxicity and <1% reported 
other grade 3 acute toxicity.  
Grade 2 late toxicity (any) at 6 and 12 months was seen in 
19% and 10.5% respectively. Any grade 3 late toxicity at 6 and 
12 months was seen 6.5% and 5% respectively. 
Local control at 3 months following radiotherapy was 88% 
(95%CI 64%-99%). Local progression free survival at 1 year was 
88% (95%CI 77%-100%) and overall survival at 1 year was 64% 
(95% CI 50%-77%).  
Conclusions: Hypofractionated radiotherapy delivered with a 
plan of the day IGART approach offers good local control with 
acceptable toxicity in a patient population not suitable for 
radical bladder treatment. This strategy is now being 
evaluated in a randomised multi-centre trial (HYBRID study; 
hypofractionated bladder radiotherapy with or without image 
guided adaptive planning).  
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) is 
used increasingly for the treatment of localised prostate 
cancer (LPC). Although there is a significant body of data on 
efficacy, few published studies have assessed toxicity more 
than once during the first 12 weeks after treatment, 
potentially underestimating acute toxicity. This information 
is essential for informed patient consent. We aimed to 
accurately define the toxicity profile by prospective two-
weekly assessment. 
Materials and Methods: Patients were treated using the 
Cyberknife® system with a dose of 36.25Gy / 5# (PTV V36.25 
Gy > 95%; prostate V40 Gy > 95%). Patients were treated on 
alternate or consecutive week days (range: 5-12 days). No 
patients received hormonal therapy. IPSS and RTOG toxicity 
was prospectively assessed at 2, 4, 6, 8, 10 and 12 weeks 
from start of treatment. Thereafter, patients were assessed 
every 3 months for the first 2 years, then 6 monthly. This 
study was given prospective approval by our institutional 
Clinical Research Committee. 
Results: Forty consecutive patients were treated; 5 low, 34 
intermediate, and 1 high NCCN risk. Median follow up was 21 
months (range: 3-38). Median IPSS score at baseline was 6 
(IQR: 4-11). Peak median IPSS score was recorded at two 
weeks (17; IQR: 8-22), returning to baseline by 4-6 weeks. 
The incidence of acute grade 2+ RTOG GU and GI toxicity was 
25% (10) and 20% (8), respectively, peaking at 2-3 weeks. 
Forty eight percent (19) received an α-blocker, either 
prophylactically (13%, 5 patients) or for urinary symptoms. 
One case of grade 3 GU toxicity occurred at 8 weeks due to 
mild transient haematuria. A single case of grade 3 GI 
toxicity occurred at 4 weeks due to a small amount of faecal 
incontinence. All acute toxicity had settled to grade 0-1 by 
week 10. No difference in acute toxicity was observed 
between patients having daily or alternate daily treatment. 
Incidence of late grade 2+ toxicity was 5% (2) for GU domain 
and 5% (2) for GI domain. Median PSA at baseline, 12 months 
and 24 months was 9, 0.96 and 0.65, respectively. 
Conclusions: Acute toxicity from SBRT for LPC peaks earlier 
than that of conventionally fractionated radiotherapy, but 
resolved rapidly and completely. Infrequent assessment risks 
underestimation of toxicity in this emerging treatment. SBRT 
should be evaluated in randomised trials, such as the PACE 
study, against current standards of care. 
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Purpose/Objective: Clinical data suggest that large radiation 
fractions are biologically superior to smaller fraction sizes in 
prostate cancer radiotherapy. Hypofractionated prostate 
stereotactic body radiotherapy aims to minimize the dose to 
the surrounding critical normal structures while delivering a 
large dose to the target volume. The CyberKnife is an 
appealing delivery system for hypofractionated radiosurgery 
due to its ability to deliver highly conformal radiation and to 
track and adjust for prostate motion in real-time. We 
compared outcomes in intermediate to high risk prostate 
cancer patients treated with cyberknife for boost after 
internsity modulated radiation therapy (IMRT) or three-
dimensional conformal radiation therapy (3-DRT).  
Materials and Methods: This study was based on a 
retrospective chart review analysis of the 46 patients treated 
with CyberKnife radiotherapy for localized prostate cancer. 
27 patients treated with 3DRT to a dose of 45 Gy in 25 
fractions and 19 patients with IMRT to same dose and all 
patients received a boost by the CyberKnife at dose of 21 Gy 
in 3 fractions. The acute toxicities were recorded using the 
RTOG acute toxicity scale and the Common Terminology 
Criteria for Adverse Events, version 3.0.  
Results: All 46 patients finished planed radiation therapy 
without any severe complication. The median follow-up for 
patients was 38 months (range 6 - 56 months). There were 
two biochemical failures in high risk patients in 3-DRT+CK 
and one in IMRT+CK group. The 3-year actuarial biochemical 
progression-free survival was 92.3% for 3-DRT+CK and 94.8% 
for IMRT+CK (p=0.752). There were no acute Grade 3 or 4 GI 
toxicities. Late Grade 3 GI toxicity, rectal bleeding, was 
noted in 2 patient in high risk group (7.4%) only in 3-DRT+CK 
group but bleeding was stopped with 3 times laser 
coagulation in one patients. There was acute Grade 3 urinary 
frequency in one patient (3.74%) of high risk group of 3-
DRT+CK group . There were no late grade 3 to 4 GU toxicity 
in both group.  
